Sun Pharma Advanced Research Co has received formal requests from members of its promoter group seeking reclassification of their shareholdings from the 'Promoter Group' category to the 'Public' category. The disclosure, made on July 27, 2026, involves a total of 59,79,182 shares, which constitute 1.85% of the company’s total equity shares. This procedural step is significant as it alters the composition of the company’s shareholding pattern, potentially affecting the classification of holdings for regulatory and compliance purposes under the Securities and Exchange Board of India (SEBI) framework.

The intimation was issued in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requests were submitted by three individuals currently classified within the promoter group. The company stated that these requests will be examined in accordance with the applicable provisions of the Listing Regulations. Following this examination, the matter will be placed before the Board of Directors for consideration. Subject to Board approval and the completion of the prescribed process, the company will submit the necessary applications to the stock exchanges.

The shareholders seeking reclassification are Mr. Sudhir Vrundavandas Valia, Mrs. Raksha Sudhir Valia, and Mrs. Krishna Vrundavandas Valia. The table below details the number of shares held by each individual and their respective percentage stakes in the company.

The reclassification process is governed by Regulation 31A of the Listing Regulations, which outlines the criteria and procedures for changing the category of shareholders. This regulation ensures that such changes are transparent and comply with broader market integrity standards. The company’s Company Secretary and Compliance Officer, Kajal Damania, signed the intimation sent to the National Stock Exchange of India Ltd. and BSE Limited.

What This Means for Shareholding Structure

The shift of 1.85% of the stake from the promoter group to the public category reduces the consolidated promoter holding while increasing the public float. For investors and analysts monitoring SPARC’s corporate governance and ownership structure, this change highlights a potential dilution in direct promoter control, albeit marginal in absolute terms. Such reclassifications are often strategic moves to meet specific regulatory thresholds or to facilitate easier trading of shares in the open market, as public category shares are generally more liquid and subject to different disclosure norms compared to promoter-held shares. The final impact on the shareholding pattern will be reflected in subsequent filings once the Board approves the reclassification.

Sun Pharma Advanced Research Company Limited has scheduled its 21st Annual General Meeting (AGM) for August 10, 2026, at 4:30 P.M. IST through video conferencing. The company has fixed August 3, 2026, as the cut-off date to determine shareholder eligibility for voting and attending the meeting. The Annual Report for the financial year 2025-26 was sent electronically to shareholders on July 16, 2026.

E-voting and Participation Details

Shareholders can exercise their voting rights through remote e-voting, facilitated by Central Depository Services (India) Limited (CDSL). The remote e-voting period commences at 9:00 A.M. IST on August 6, 2026, and concludes at 5:00 P.M. IST on August 9, 2026. Members who have not cast their votes remotely may vote during the AGM via the e-voting system, provided they are present through video conferencing.

Key Meeting Dates

Shareholders holding shares in physical form or those who have not registered their email addresses must follow specific instructions detailed in the AGM notice to access the e-voting facility. The company has mandated that physical shareholders update their KYC details, including PAN, nomination, and bank account information, with the Registrar and Transfer Agent.